TCGA-DK-AA6M-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 51.97109067
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- ALLOGRAFT_REJECTION+0.470
- MYC_TARGETS_V1+0.470
- MYC_TARGETS_V2+0.460
- E2F_TARGETS+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.430
- DNA_REPAIR+0.420
- INFLAMMATORY_RESPONSE+0.400
- IL2_STAT5_SIGNALING+0.380
Top 10 suppressed
- BILE_ACID_METABOLISM-0.270
- PANCREAS_BETA_CELLS-0.230
- HEDGEHOG_SIGNALING-0.200
- FATTY_ACID_METABOLISM-0.180
- PEROXISOME-0.170
- PROTEIN_SECRETION-0.170
- SPERMATOGENESIS-0.170
- CHOLESTEROL_HOMEOSTASIS-0.130
- KRAS_SIGNALING_DN-0.130
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-8201-01A-11R-2247-07 | — | cohortA1 | 0.896 |
| 2 | 91E04630-B2A7-448E-8C80-580818C9D7E6 | — | — | 0.895 |
| 3 | TCGA-UY-A9PB-01A-11R-A38B-07 | — | — | 0.893 |
| 4 | 25B5E54F-5858-454C-9B23-440A82450912 | — | — | 0.887 |
| 5 | TCGA-GU-A762-01A-11R-A33J-07 | — | — | 0.886 |
| 6 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.885 |
| 7 | TCGA-4Z-AA86-01A-11R-A39I-07 | — | — | 0.871 |
| 8 | 81B10E10-884A-46EB-9F28-758D805FB9B1 | — | — | 0.869 |
| 9 | BS_QX12J6W1 | ATRT | — | 0.868 |
| 10 | FD3CFD0E-E8D9-4A57-A9F0-4FB519B7E459 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |